Straits Times Index
3,217.41 +10.42 (+0.32%) Nikkei
31,857.62 -14.90 (-0.05%) Hang Seng
17,809.66 +436.63 (+2.51%) FTSE 100
7,608.08 +6.23 (+0.08%) Bitcoin USD
26,926.85 -137.52 (-0.51%) CMC Crypto 200
579.66 +0.90 (+0.15%)
CHRS Dec 2023 17.500 call
| Previous close | 0.1000 |
| Open | 0.1000 |
| Bid | 0.0000 |
| Ask | 0.1500 |
| Strike | 17.50 |
| Expiry date | 2023-12-15 |
| Day's range | 0.1000 - 0.1000 |
| Contract range | N/A |
| Volume | |
| Open interest | 117 |
ZacksCoherus (CHRS) Gets CRL for Udenyca Onbody, Shares Down
Coherus (CHRS) gets CRL for the biologics license application supplement for Udenyca Onbody, an on-body injector presentation of Udenyca.
Motley FoolWhy Coherus BioSciences Stock Was Plunging This Week
Unfortunately for shareholders of Coherus BioSciences (NASDAQ: CHRS), that's what happened to their company after market hours last Friday. Following that, its stock price was falling by 10% week to date as of early Friday morning, according to data compiled by S&P Global Market Intelligence. Among these incoming S&P SmallCap 600 constituents are pizza slinger Papa John's International, storied athletic apparel retailer Foot Locker, and JetBlue Airways.
Motley FoolWhy Coherus BioSciences Stock Popped Today
Shares of Coherus BioSciences (NASDAQ: CHRS) soared 17.7% on Thursday, according to data provided by S&P Global Market Intelligence, after the biotech company announced better-than-expected quarterly results. Coherus' net revenue climbed a whopping 81% year over year to $58.7 million, translating to an adjusted net loss of $32.8 million, or $0.38 per share. Analysts, on average, were anticipating a wider net loss of $0.48 per share on lower revenue of $50.5 million.
